Hims & Hers Health, Inc. Class A Common Stock (HIMS)

Short interest totalled about $1.39 billion, or roughly 42.83% of the float, according to S3 Partners.

On March 9, 2026, a new Novo Nordisk pact reshaped this telehealth player’s GLP-1 strategy, margins, and legal risk profile.

The financial landscape on March 9, 2026, has reached a critical tipping point, marking one of the most aggressive sector rotations in modern market history. As technology-heavy indices struggle to find their footing under the weight of "AI fatigue" and new trade pressures, investors have staged a massive exodus into

Hims & Hers stock traded more than 40% higher after the deal was announced.

Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 41.7% in the morning session after the company announced a collaboration wi...

Date: March 9, 2026Sector: Healthcare TechnologyCompany: Hims & Hers Health, Inc. (NYSE: HIMS) Introduction As of March 9, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at perhaps the most critical juncture in its nine-year history. Once viewed as a disruptive "millennial-focused" telehealth startup specializing in hair loss and sexual health, the company [...]

Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.

Data from Stocktwits showed that retail sentiment on SPY and QQQ remains ‘bearish.’

Lupton Capital CEO Jonah Lupton said the potential agreement could include both injectable and oral GLP-1 drugs.

According to J.P. Morgan, the market for weight-loss drugs will become one of the biggest and fastest-growing in healthcare.

President Trump's tariffs have been overturned, throwing the market into even more chaos in 2026.

The stake reduction comes as Hims navigates regulatory scrutiny over weight-loss drugs, while expanding into other healthcare categories.

NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a precarious regulatory and legal bind. As of March 4, 2026, the company finds itself at a crossroads, battling

The warnings involve compounded versions of Semaglutide, Tirzepatide and Liraglutide, the active ingredients in Wegovy, Ozempic and Mounjaro.

The Futurum Group CEO Daniel Newman said Hims is the “most likely public company play” for peptides at scale.

Why does the shortest month of the year sometimes feel like the longest?

The stock is down big of late, but the business is by no means doomed.

Shares of Hims & Hers Health, Inc. (NASDAQ: HIMS) are rising Monday after Secretary of Health and Human Services Robert F. Kennedy Jr. said on the Joe Rogan podcast that several peptide compounds, a popular wellness treatment, would be added to an approval list.